BIND Biosciences Inc.
This article was originally published in Start Up
Executive Summary
BIND Biosciences generates nanoparticles with unique targeting agents that allow them to home in on cancerous cells with deadly precision. Because it's impossible to mathematically design the optimal particle, BIND scientists have created large combinatorial libraries of nanoparticles with different biophysical and chemical properties.You may also be interested in...
In Oncology Drug Boom, Can Next-Gen Cytotoxics Fit In?
The drug industry has placed a bull's eye on the field of oncology as a key therapeutic area, but not all oncology players are created equal.
FDA Seeks Public Input To Develop Guidance For Nanotechnology In Pharmaceuticals
Sept. 8 public meeting requests input on safety, efficacy points to consider for using nanotech in drugs, biologics.
TransGenex Nanobiotech Inc.
TransGenex Nanobiotech is taking a multi-pronged approach to building a nanotechnology company. In the short term, the company is generating revenue from sales of its custom nanoparticles and its Nanogene reagents that can be used to deliver genes to cells. It is also using its technology to develop diagnostic platforms, especially for lung and ovarian cancer. Finally, TransGenex plans to develop its own novel drug candidates. It's focusing first on products with anti-inflammatory properties, which could find application in asthma as well as several cancers.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports